ArticleAntimicrobial agents and chemotherapy2019
Shortening Buruli Ulcer Treatment with Combination Therapy Targeting the Respiratory Chain and Exploiting Mycobacterium ulcerans Gene Decay.
Article in Antimicrobial agents and chemotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Bedaquiline for treatment of non-tuberculous mycobacteria (NTM): a systematic review and meta-analysis.The Journal of antimicrobial chemotherapy · 2024Pooled it
- High-dose rifampicin and clarithromycin for 4 weeks versus standard-dose rifampicin and clarithromycin for 8 weeks to treat Buruli ulcer: An open-label, individually randomized, controlled trial in Ghana.PLoS neglected tropical diseases · 2026Trial
- Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial.Lancet (London, England) · 2020Trial
- Buruli ulcer.Nature reviews. Disease primers · 2025Review
- Review
- Unprecedented in vivo activity of telacebec against Mycobacterium leprae.PLoS neglected tropical diseases · 2025Article
- Structural and mechanistic study of a novel inhibitor analogue ofnpj drug discovery · 2025Article
- Mycobacterium ulcerans challenge strain selection for a Buruli ulcer controlled human infection model.PLoS neglected tropical diseases · 2024Article
- The Many Hosts of Mycobacteria 9 (MHM9): A conference report.Tuberculosis (Edinburgh, Scotland) · 2023Article
- Can membrane composition traffic toxins? Mycolactone and preferential membrane interactions.Biophysical journal · 2022Article
- Drug Efficacy Testing in the Mouse Footpad Model of Buruli Ulcer.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Impact of Dose, Duration, and Immune Status on Efficacy of Ultrashort Telacebec Regimens in Mouse Models of Buruli Ulcer.Antimicrobial agents and chemotherapy · 2021Article
- In vitro activity of SPR719 against Mycobacterium ulcerans, Mycobacterium marinum and Mycobacterium chimaera.PLoS neglected tropical diseases · 2021Article
- Ultra-short-course and intermittent TB47-containing oral regimens produce stable cure against Buruli ulcer in a murine model and prevent the emergence of resistance forActa pharmaceutica Sinica. B · 2021Article
- Toward a Single-Dose Cure for Buruli Ulcer.Antimicrobial agents and chemotherapy · 2020Article
- Telacebec (Q203)-containing intermittent oral regimens sterilized mice infected with Mycobacterium ulcerans after only 16 doses.PLoS neglected tropical diseases · 2020Article
- Telacebec for Ultrashort Treatment of Buruli Ulcer in a Mouse Model.Antimicrobial agents and chemotherapy · 2020Article
- Pharmacologic management ofExpert review of clinical pharmacology · 2020Review
- The Many Hosts of Mycobacteria 8 (MHM8): A conference report.Tuberculosis (Edinburgh, Scotland) · 2020Review
- Targeting Autophagy as a Strategy for Developing New Vaccines and Host-Directed Therapeutics Against Mycobacteria.Frontiers in microbiology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Buruli ulcer is treatable with antibiotics. An 8-week course of rifampin (RIF) and either streptomycin (STR) or clarithromycin (CLR) cures over 90% of patients. However, STR requires injections and may be toxic, and CLR shares an adverse drug-drug interaction with RIF and may be poorly tolerated. Studies in a mouse footpad infection model showed that increasing the dose of RIF or using the long-acting rifamycin rifapentine (RPT), in combination with clofazimine (CFZ), a relatively well-tolerated antibiotic, can shorten treatment to 4 weeks. CFZ is reduced by a component of the electron transport chain (ETC) to produce reactive oxygen species toxic to bacteria. Synergistic activity of CFZ with other ETC-targeting drugs, the ATP synthase inhibitor bedaquiline (BDQ) and the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.